1. Home
  2. SINT vs BCDA Comparison

SINT vs BCDA Comparison

Compare SINT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$2.35

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$0.90

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SINT
BCDA
Founded
1996
N/A
Country
United States
United States
Employees
N/A
21
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
12.9M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
SINT
BCDA
Price
$2.35
$0.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.00
$25.00
AVG Volume (30 Days)
39.0K
161.1K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
59.45
N/A
EPS
N/A
N/A
Revenue
$1,018,000.00
N/A
Revenue This Year
$30.26
N/A
Revenue Next Year
$413.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$0.84
52 Week High
$6.78
$2.45

Technical Indicators

Market Signals
Indicator
SINT
BCDA
Relative Strength Index (RSI) 45.43 32.42
Support Level $2.28 $0.84
Resistance Level $2.98 $1.30
Average True Range (ATR) 0.15 0.08
MACD 0.01 -0.01
Stochastic Oscillator 38.49 20.18

Price Performance

Historical Comparison
SINT
BCDA

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: